Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rituximab + ifosfamide + carboplatin + etoposide
- Development stage
- Phase 3
- Lead developer
- Biogen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Rituximab + ifosfamide + carboplatin + etoposide (commonly known as R-ICE) is a combination chemotherapy regimen used primarily for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma and certain other lymphomas. Rituximab is a monoclonal antibody that targets the CD20 protein on B cells, marking them for destruction by the immune system. Ifosfamide, carboplatin, and etoposide are cytotoxic chemotherapy agents that work by damaging DNA in rapidly dividing cells, leading to cell death. This combination leverages both targeted immunotherapy (rituximab) and broad-spectrum cytotoxic effects (ifosfamide, carboplatin, etoposide) to maximize anti-tumor activity[1][2][3][4].
- Other names
- rituximab infusional ifosfamide carboplatin etoposiderituximab fractionated ifosfamide carboplatin etoposide
02
Targets
Beyond the preview
Go deeper on rituximab + ifosfamide + carboplatin + etoposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rituximab + ifosfamide + carboplatin + etoposide.